Annual General Shareholders’ Meeting 2023 – June 16, 2023 - 2nd call – Expected to be held on this date / June 15, 2023 - 1st call. Click here.
Patients inspire and motivate our science. Our ever-growing knowledge of the causes of many chronic, rare and prevalent diseases is driving the development of potential new treatment options derived both from our expertise in human plasma as well as a new class of recombinant antibody drugs and small-molecule candidates. We probe deeply into a range of pathologies – from immunodeficiencies to respiratory disorders to age-related conditions – to create innovative therapeutics that adhere to the highest scientific, ethical and quality standards to help improve people’s lives.
Grifols treatments center on immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. Each area features therapies helping patients today as well as boundary-pushing research leading to the next groundbreaking discoveries. The next wave of Grifols innovation has the potential to significantly transform healthcare.
We combine our longstanding plasma excellence with new technology platforms to accelerate the development of novel treatments.
Grifols is increasingly diversifying its therapeutic approach with a portfolio of innovative non-plasma treatments such as a new class of recombinant protein candidates and small-molecule pharmaceuticals.
External investments, alliances and partnerships complement our in-house efforts and contribute to a powerful innovation ecosystem dedicated to treating patients.
Our global network of three innovation hubs is home to more than 1,200 investigators working on everything from early discovery to advanced clinical trials.
Learn more
